A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) (VELOCITY-Lung)
The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous treatment for metastatic NSCLC. Substudy-03 will compare the different novel combinations versus standard of care in participants with resectable stage II-III NSCLC. The primary objectives of this study are: Substudy-01 and Substudy-02: To evaluate the objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Substudy-03: To evaluate the efficacy of treatment combinations based on complete pathological response (pCR) rate.
View More
Age
18 Years +
Sex
All
Healthy Volunteers
No
Medical Condition
Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
Gender
N/A
Date
March 2023 - January 2027
Study Type
Interventional
Study Phase
Phase 2
Product
Zimberelimab (ZIM), Domvanalimab (DOM), Sacituzumab govitecan-hziy (SG), Etrumadenant (ETRUMA), Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Docetaxel, Nivolumab
Tucson, Arizona, United States, 85711
Tucson, Arizona, United States, 85711
Denver, Colorado, United States, 80218
Denver, Colorado, United States, 80218
Fort Wayne, Indiana, United States, 46845
Saint Louis, Missouri, United States, 63110
Saint Louis, Missouri, United States, 63110
Saint Louis, Missouri, United States, 63110
Cincinnati, Ohio, United States, 45242
Cincinnati, Ohio, United States, 45242
Eugene, Oregon, United States, 97401
Eugene, Oregon, United States, 97401
Austin, Texas, United States, 78745
Austin, Texas, United States, 78745
Fairfax, Virginia, United States, 22031
Fairfax, Virginia, United States, 22031
Seattle, Washington, United States, 98109
Seattle, Washington, United States, 98109
Hong Kong, Hong Kong
Hong Kong, Hong Kong
Hong Kong, Hong Kong
Hong Kong, Hong Kong
New Territories, Hong Kong
Haifa, Israel, 3525408
Haifa, Israel, 3525408
Haifa, Israel, 3525408
Jerusalem, Israel, 9103102
Jerusalem, Israel, 9103102
Jerusalem, Israel, 9103102
Jerusalem, Israel, 91120
Tel Aviv-Yafo, Israel, 64239
Tel Aviv-Yafo, Israel, 64239
Tel Aviv-Yafo, Israel, 64239
Cheongju-si, Korea, Republic of, 28644
Cheongju-si, Korea, Republic of, 28644
Goyang, Korea, Republic of, 410769
Goyang, Korea, Republic of, 410769
Goyang, Korea, Republic of, 410769
Gwangju, Korea, Republic of, 61469
Gyeonggi-do, Korea, Republic of, 463-707
Seo-gu, Korea, Republic of, 49267
Seoul, Korea, Republic of, 05505
Seoul, Korea, Republic of, 05505
Seoul, Korea, Republic of, 05505
Seoul, Korea, Republic of, 06351
Seoul, Korea, Republic of, 06351
Seoul, Korea, Republic of, 120-752
Seoul, Korea, Republic of, 120-752
Seoul, Korea, Republic of, 463-707
Seoul, Korea, Republic of, 463-707
Seoul, Korea, Republic of, 8308
Changhua City, Taiwan, 500-06
Changhua City, Taiwan, 500-06
Changhua City, Taiwan, 500-06
Kaohsiung City, Taiwan, 80756
Kaohsiung City, Taiwan, 80756
Kaohsiung City, Taiwan, 80756
Kaohsiung, Taiwan, 83301
Kaohsiung, Taiwan, 83301
Kaohsiung, Taiwan, 83301
Taipei City, Taiwan, 100
Taipei City, Taiwan, 100
Birmingham, United Kingdom, B9 5SS
Birmingham, United Kingdom, B9 5SS
London, United Kingdom, E1 1BB
London, United Kingdom, E1 1BB
Share Trial